Agenus testing shows promising results for herpes vaccine

Agenus vaccine reduces viral burden
Agenus vaccine reduces viral burden | Courtesy of herpes-coldsores.com
Agenus Inc. -- an immune-oncology company that creates heat shock protein peptide-based vaccines, checkpoint modulators (CPMs), and adjuvants -- recently announced promising results from its HerpV synthetic vaccine Phase 2 trial.

The vaccine is meant to treat patients who have genital Herpes Simplex Virus-2 (HSV-2). HerpV is comprised of a mixture of peptides for HSV-2 antigens as well as the company’s QS-21 Stimulon adjuvant.

The Phase 2 trial was randomized, multi-center and double-blind, which is the gold standard for trials. The majority of the patients had immune responses to the vaccine after they had received a series of vaccines and a booster dose at the six-month mark.

Over half of the subjects involved in the trial showed a strong anti-HSV cytotoxis T-cell immune response. These patients also showed a 75 percent decrease in their overall viral load. This decrease suggests that it may reduce the severity and incidence of herpes outbreaks as well as a decrease in transmission of the virus.

"We are pleased that the cellular immune response observed with HerpV vaccination is associated with a significant reduction in viral replication in the genital tract," Agenus Chief Scientific Officer Robert Stein said. "The fact that our vaccine contains multiple HSV- 2 antigens may contribute to its desired effects. We look forward to advancing discussions with potential partners to take this program into the next phase of clinical research."

Organizations in this Story

Agenus Inc

Want to get notified whenever we write about Agenus Inc ?
Next time we write about Agenus Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.